key: cord-0717225-vz91dfb7
authors: Fan, Bingwen Eugene
title: Hematologic parameters in patients with COVID‐19 infection: a reply
date: 2020-05-29
journal: Am J Hematol
DOI: 10.1002/ajh.25847
sha: cbb6646b6cad8cb0fbdcd7946b68ec15112fb3ad
doc_id: 717225
cord_uid: vz91dfb7

nan

To the Editor:

We thank Dr Sahu and Dr Siddiqui for adding further input on the effect of COVID 19 infection on the blood system, in their correspondence to our letter to the American Journal of Hematology. 1 We did not specifically look at coagulation abnormalities in our correspondence to AJH, but we have noted these have been already As mentioned in our correspondence, our primary focus was on hematologic parameters and we did not cover the scope of any specific data on thrombosis and bleeding. We have however, further published in a separate letter to the American Journal of Hematology about the usage of blood and blood products, 6 which may answer partially the concerns of risk of bleeding in our population of patients.

None of our patients we studied with COVID-19 infection had hematologic malignancies at the point of submitting our letter, but we do recognize that these immunosuppressed patients are particularly vulnerable and may likely experience greater morbidity and mortality when having a COVID-19 infection. 

Hematologic parameters in patients with COVID-19 infection

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Prominent changes in blood coagulation of patients with SARS-CoV-2 infection

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

ISTH Interim Guidance on Recognition and Management of Coagulopathy in COVID-19

Blood and blood product use during COVID-19 infection